Abstract:PI3K comprise a group of lipid kinases mainly made up of three classes and have a particular role in signal transduction. The aberration of class IA PI3K is most frequently shown in cancer. The computation techniques have been applied for the identification of potent compounds. This involved the generation of a library of novel compounds (2700) through R-group enumeration study. The screening process utilized a combination of pharmacophore-based virtual screening and various docking algorithms, leading to the discovery of ten novel compounds. The docking studies against PI3K kinase highlighted MSA6 and MSA7 as the most promising compounds, with docking scores of -9.03 and -9.0 kcal/mol, respectively. Results of docking studies of all derivatives confirmed satisfactory binding mode of the compounds within the active site of the target protein PI3K kinase. The screened pyrazolo-pyridine derivatives (MSA1-MSA10) were synthesized and evaluated as anti-cancer agents against NSCLC using A549 cell line. MSA6 showed the dose dependent enhancement in ROS production at concentration of 10 and 20 μM in A549 cells. MSA6 triggered caspase 3 cleavage in lung cancer cells in a dose-dependent manner. MSA6 treatment at 10 and 20 μM levels boosted NF-κβ expression in the cytoplasm while decreasing it in the nucleus, as demonstrated by flow cytometry with an anti-NF-κβ antibody. The modulation of PI3K activity have been observed at 10 μM and 20 μM concentration of MSA6. A549 cells treated with MSA6 with 20 μM showed significant reduction in wound healing in cancerous cell. A549 cells treated with 20 μM showed significantly reduction in number of colonies compared to control group. Compound MSA6 having a methyl group at the para position of phenyl ring at imine carbon and phenyl ring substitution at nitrogen of pyrazole ring exhibited remarkable growth inhibitory activity with IC 50 value of 49.23 μM. Based on the above results, pyrazolo-pyridine derivatives can be used for the further development of novel PI3K kinase inhibitors as anticancer agents.

Design and synthesis of novel quinazolinone-based pyruvate kinase M2 activators as selective inhibitors of oral cancer cells

Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study

Discovery of Novel Naphthoquinone Derivatives As Inhibitors of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase.

Combining Structure-Based Pharmacophore Modeling, Virtual Screening, and in Silico ADMET Analysis to Discover Novel Tetrahydro-Quinoline Based Pyruvate Kinase Isozyme M2 Activators with Antitumor Activity

Synthesis of Novel 7-Azaindole Derivatives Containing Pyridin-3-ylmethyl Dithiocarbamate Moiety As Potent PKM2 Activators and PKM2 Nucleus Translocation Inhibitors.

Computational Design, Chemical Synthesis, and Bioevaluation of Pyrimidinyl‐Indoles for Targeting Breast Cancer Cells

Combined computational and synthetic strategies for the development of potent pyrazolo-pyridine derivatives as anticancer agents

New Pyridin-3-ylmethyl Carbamodithioic Esters Activate Pyruvate Kinase M2 and Potential Anticancer Lead Compounds.

Synthesis and Antitumor Activity of Novel 2, 3-Didithiocarbamate Substituted Naphthoquinones As Inhibitors of Pyruvate Kinase M2 Isoform.

Novel 2-Sulfanylquinazolin-4(3 H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study

Modulation of tumour pyruvate kinase M2 and suppression of cancer cell proliferation using natural and synthetic antioxidants

Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study

Synthesis of Novel Sulfonamide Derivatives Containing Pyridin-3-ylmethyl 4-(Benzoyl)piperazine-1-carbodithioate Moiety As Potent PKM2 Activators.

Novel purine derivatives as selective CDK2 inhibitors with potential anticancer activities: Design, synthesis and biological evaluation

Design, Synthesis, and Molecular Docking of Quinazolines Bearing Caffeoyl Moiety for Targeting of PGK1/PKM2/STAT3 Signaling Pathway in the Human Breast Cancer

PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues

Novel quinoline-4-carboxamide derivatives potentiates apoptosis by targeting PDK1 to overcome chemo-resistance in colorectal cancer: Theoretical and experimental results

Targeting hexokinase 2 for oral cancer therapy: structure-based design and validation of lead compounds

Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition

Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations

Determination of Inhibitory Effect of PKM2 Enzyme and Antitumoral Activity of Novel Coumarin-Naphthoquinone Hybrids